Autopsy report · NCT04372082

Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19

“evidence showed chloroquine is not effective against COVID-19”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

University Hospital, Lille

Sponsor type

University, hospital or other

Conditions

Sars-CoV2

Interventions

Standard of care (SOC); Hydroxychloroquine; Association of diltiazem and niclosamide

Participants

0

Trials that died the same way

• Pedicle Osteotomy for Stenosis Trial
  “In light of the ongoing COVID-19 pandemic and its impact on clinical trials” (61% match in meaning)
• Non Verbal Communication and Dementia
  “health context of covid-19” (61% match in meaning)
• Pre-etching of Dentin Before Restorations With High Viscosity Glass Ionomer Cement
  “The Outbreak of COVID-19.” (59% match in meaning)
• Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
  “lack of Covid-19 patients” (58% match in meaning)
• Virtual Reality for the Treatment of Chronic Low Back Pain
  “Due to the impact of COVID-19” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.